Apoptosis in cardiovascular remodeling--effect of medication

Cardiovasc Drugs Ther. 2001 Nov;15(6):539-45. doi: 10.1023/a:1013723922582.

Abstract

In the last decade, apoptosis has emerged as a key determinant of target organ damage in cardiovascular diseases. The suggestion that increased cardiomyocyte apoptosis participates in the etiology of heart failure probably contributed to the negative view of the prevalence of apoptosis in the field of cardiovascular diseases. However, we and others have shown that up-regulation of apoptosis in certain cardiovascular cells may contribute to the beneficial action of antihypertensive drugs on target-organ structure. As an explanation for this apparent discrepancy, the same stimulus, e.g. angiotensin II, can induce apoptosis or stimulate cell growth in different cell types (e.g., cardiomyocytes and fibroblasts, respectively). Using the angiotensin pathway as a paradigm, this review proposes an integrative view of cell growth and cell death regulation in cardiovascular cells in order to illustrate how cell-specific responses to the same stimulus may in part explain the patterns of cell population dynamics during the development and treatment of target organ damage in hypertension.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiotensin Receptor Antagonists
  • Antihypertensive Agents / pharmacology
  • Antihypertensive Agents / therapeutic use
  • Apoptosis / drug effects
  • Apoptosis / physiology*
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / physiopathology
  • Coronary Vessels / pathology
  • Coronary Vessels / physiopathology
  • Endothelium, Vascular / pathology
  • Endothelium, Vascular / physiopathology
  • Heart / drug effects
  • Heart / physiopathology
  • Heart Failure / drug therapy
  • Heart Failure / physiopathology
  • Humans
  • Hypertension / drug therapy
  • Hypertension / physiopathology
  • Muscle, Smooth, Vascular / pathology
  • Muscle, Smooth, Vascular / physiopathology
  • Ventricular Remodeling / drug effects
  • Ventricular Remodeling / physiology*

Substances

  • Angiotensin Receptor Antagonists
  • Antihypertensive Agents